From personalized health solutions to microbiome testing, Macrogen’s global mission redefines the role of DNA in healthcare and self-discovery.
“Every living creature possesses its own genetic blueprint,” declared Jacques Monod, French biochemist and 1965 Nobel Prize laureate in Physiology or Medicine. Inspired by this profound insight, Macrogen, established in 1997, has emerged as a global pioneer in genome sequencing and testing, pushing the boundaries of what is possible with our DNA. With a mission to democratize access to genomic information, Macrogen has launched its latest initiative, GenTok. This innovative platform aims to provide affordable and precise genetic services to over 10 million people worldwide within the next five years.
“Right now, we are focusing on shifting from treatment to prevention and expanding the use of genetic analysis,” says Macrogen Chairman Jeong-Sun Seo. By analyzing both genetic and microbiome data, GenTok offers a holistic approach to wellness, further enhanced with an AI-powered chatbot that delivers highly personalized health consultations. The platform not only transforms how individuals use their personal genome but also serves as an educational tool, empowering users to make informed lifestyle choices and proactively manage their well-being.
Initially developed for doctors and medical institutions, GenTok utilizes DNA testing to help healthcare professionals prescribe medications tailored to personal genome profiling. This personalized approach improves treatment outcomes, shortens recovery times, and reduces costs for healthcare systems. “Macrogen’s GenTok offers an opportunity to experience genetic testing in a way that is engaging and educational,” explains Chairman Seo. Beyond healthcare, GenTok resonates with younger generations who are less focused on diseases and more interested in self-discovery.
Another significant contribution is the GenTok Biome service that “analyzes 11 wellness indicators like bloating, happiness, sleep, and immunity, as well as 14 nutrient metabolism scores and 19 probiotics approved by the Ministry of Food and Drug Safety,” says Chairman Seo. Accessible through the GenTok app, users can manage their health from home based on their gut environment, which evolves with lifestyle and habits. With plans to expand into regular monitoring and specialized microbiome analyses, and bolstered by Ubiome’s intellectual property, Macrogen is poised to lead a microbiome market projected to grow to $10.09 billion by 2026.
Driving this innovation is Macrogen’s unwavering commitment to staying at the technological forefront. Often the first in Asia–and sometimes in the world—to adopt groundbreaking tools such as NovaSeq X, Revio, and UG100, Macogen integrates top-tier equipment at their Korea HQ and extends these advancements to affiliates across Japan, APAC, Europe, the US, and Latin America. Leveraging ultra-precise genome analysis tools from Illumina and PacBio’s long-read sequencing technology enables Macrogen to decode complex DNA sequences, providing deep insight into structural variations and gene rearrangements.
Building on its technological leadership, Macrogen is anchoring its global strategy with the Songdo Global Campus, an 18,800-square-meter facility set to become Asia’s largest genome big data hub by 2026. This genome foundry will integrate genome data with AI, streamlining the entire genome business value chain and driving digital healthcare transformation. Beyond Songdo, Macrogen is expanding its global reach. In Europe, the company’s “Genome Supermarkets” span key markets like Belgium, Italy, France, and Germany, with plans to expand into Madrid and the U.S. market. With partnerships across 160 countries and over 20,000 research institutions, Macrogen is also tailoring solutions to local needs in Latin America, the Middle East, Southeast Asia, and Oceania, driving progress in genome technologies through collaboration and localized strategies.
Global Network
Macrogen’s vision reaches far beyond the present, aiming to unlock the full potential of genomics for the benefit of humanity. “We see genetic blueprints as a kind of GPS navigator, guiding future advancements,” shares Chairman Seo. The company’s ultimate goal is to make DNA testing available to people everywhere, empowering them to lead healthier, more fulfilling lives. Beyond this, the chairman dreams of using genome sequencing to address profound scientific mysteries and unanswered questions. With its bold ambitions and innovative strategies, Macrogen is charting a course toward a future where precision medicine and genome sequencing are within reach for all.
Discover the article on Newsweek.com/Macrogen
0 COMMENTS